Evidence map›Paper›PMID 37217993›Full record

ArticleWorld journal of surgical oncology2023

TREM-1 as a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma.

Yaling Pu, Danyang Cai, Lingling Jin, Fenfen Xu, Enru Ye, Lina Wu, Licai Mo, Suzhi Liu, Qunyi Guo, Gang Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yaling PuTaizhou Hospital of Zhejiang Province, Shao Xing University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Danyang CaiDepartment of Radiation Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Lingling JinDepartment of Pathology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Fenfen XuDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Enru YeDepartment of Pathology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Lina WuDepartment of Pathology, Enze Hospital, Taizhou Enze Medical Center, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Licai MoDepartment of Urology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Suzhi LiuTaizhou Hospital of Zhejiang Province, Shao Xing University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China. liusz@enzemed.com.
Qunyi GuoDepartment of Hematology and Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China. guoqunyi@163.com.
Gang WuDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China. weichen_star@126.com.
Wenzhou Medical University · CNZhejiang Taizhou Hospital · CN

Funding

Licai,Mo 2022ZB388
6 · The paper itself

Abstract

backgroundThe tumor immune microenvironment plays a crucial role in the efficacy of various therapeutics. However, their correlation is not yet completely understood in Clear cell renal cell carcinoma (ccRCC). This study aimed to investigate the potential of TREM-1 as a potential novel biomarker for ccRCC.

methodsWe constructed a ccRCC immune prognostic signature. The clinical characteristics, the status of the tumor microenvironment, and immune infiltration were analyzed through the ESTIMATE and CIBERSORT algorithms for the hub gene, while the Gene Set Enrichment Analysis and PPI analysis were performed to predict the function of the hub gene. Immunohistochemical staining was used to detect the expression of TREM-1 in renal clear cell carcinoma tissues.

resultsThe CIBERSORT and ESTIMATE algorithms revealed that TREM-1 was correlated with the infiltration of 12 types of immune cells. Therefore, it was determined that TREM-1 was involved in numerous classical pathways in the immune response via GSEA analysis. In Immunohistochemical staining, we found that the expression of TREM-1 was significantly upregulated with increasing tumor grade in renal clear cell carcinoma, and elevated TREM-1 expression was associated with poor prognosis.

conclusionsThe results suggest that TREM-1 may act as an implicit novel prognostic biomarker in ccRCC that could be utilized to facilitate immunotherapeutic strategy.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsHumansPrognosisTriggering Receptor Expressed on Myeloid Cells-1Tumor MicroenvironmentTriggering Receptor Expressed on Myeloid Cells-1Clear cell renal cell carcinomaImmune-related signatureThe Cancer Genome AtlasTREM-1Tumor immune microenvironment

Identifiers

PMID37217993
PMCPMC10204254
OpenAlexW4377565820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.